Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance

Study Overview
=================
Brief Summary
-----------------
The investigator's purpose is to study the population pharmacokinetics of commonly used antimicrobial agents in children of bacterial meningitis with augmented renal clearance and assess dosage individualization feasibility.

Detailed Description
-----------------
The investigator's purpose is to study the population pharmacokinetics of meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid in children of bacterial meningitis with augmented renal clearance and assess dosage individualization feasibility. In this study, the investigator will detect drug concentration in both plasma and cerebrospinal fluid to construct population pharmacokinetics.

Official Title
-----------------
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance

Conditions
-----------------
Bacterial Meningitis, Augmented Renal Clearance

Intervention / Treatment
-----------------
* Drug: meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children have been diagnosed with bacterial meningitis with augmented renal clearance (eGFR ≥ 160 mL/(min*1.73m2)); Age: 2 months-18 years; Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and/ or linezolid used as part of regular treatment; Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid was administered intravenously. Exclusion Criteria: Patients who die within the treatment cycle; Severe congenital malformation; Receive other systemic experimental drug therapy; Other factors that the researchers consider unsuitable for inclusion.

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)<br>The use of antimicrobial agents depends on the clinical practice. | Drug: meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid<br>* The use of antimicrobial agents depends on the clinical practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid. | To detect the peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration. | at (5-10) minutes after intravenous administration | 
| The random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid. | To detect the random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration. | at (0.5-10) hours after intravenous administration | 
| The trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid. | To detect the trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration. | at 1-2 hours before the next administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical response | Blood routine examination, cerebrospinal fluid routine examination and infection indicators (C-reaction protein, procalcitonin) | Through study completion, an average of 14 days |